Talimogene laherparepvec (TVEC)

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, UNC Lineberger Comprehensive Cancer Center

Conditions

Lung CancerMalignant Pleural EffusionMelanomaMerkel Cell CarcinomaOther Solid TumorsStage IV Metastatic Cancer

Phase 1

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

TerminatedNCT03597009

UNC Lineberger Comprehensive Cancer CenterLung Cancer, Malignant Pleural Effusion, Stage IV Metastatic Cancer

Start: 2019-03-06End: 2020-02-12Updated: 2021-04-20

Phase 2

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

CompletedNCT02819843

Memorial Sloan Kettering Cancer CenterMelanoma, Merkel Cell Carcinoma, Other Solid Tumors

Start: 2016-06-21End: 2024-02-22Updated: 2025-01-29

Related Papers

A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.

Journal of Clinical Oncology2023-06-012 citations